Insomnia and Somnolence Associated With Second-Generation Antidepressants During the Treatment of Major Depression: A Meta-Analysis

@article{Alberti2015InsomniaAS,
  title={Insomnia and Somnolence Associated With Second-Generation Antidepressants During the Treatment of Major Depression: A Meta-Analysis},
  author={Siegfried Alberti and Alberto Chiesa and Costanza Andrisano and Alessandro Serretti},
  journal={Journal of Clinical Psychopharmacology},
  year={2015},
  volume={35},
  pages={296–303}
}
Background Sleep reduction or enhancement is frequently observed with second-generation antidepressant treatments, and they can be beneficial or harmful depending on the symptom profile of each subject. Nevertheless, relatively little attention has been given so far to rank those effects across compounds. The aim of this meta-analysis is to provide quantitative data about short-term rates of insomnia and somnolence associated with 14 second-generation antidepressants during the treatment of… 
The preclinical discovery and development of agomelatine for the treatment of depression
TLDR
There is now evidence supporting the clinical efficacy and safety profile of agomelatine in the acute-phase treatment of MDD, and findings of post-marketing research on safety, efficacy, and cost-effectiveness of the drug are examined.
Pharmacological treatment for insomnia in patients with major depressive disorder
TLDR
Smartphones and personal devices offer a promising strategy with the use of passive, long lasting, and ecologically valid assessments despite the lack of studies specifically targeting insomnia in individuals with MDD.
Antidepressants and Their Impact on Sleep
TLDR
Preclinical studies have shown potential antidepressant effects of orexin antagonists, which are used to treat insomnia, and low-dose doxepin is the only FDA-approved antidepressant for insomnia.
Association of sleep among 30 antidepressants: a population-wide adverse drug reaction study, 2004–2019
TLDR
Among the thirty tested antidepressants, consistent with the original hypothesis, amoxepine has strongest 5-HT2C receptor binding affinity and has the highest reporting odds of somnolence.
Effects of desvenlafaxine versus placebo on MDD symptom clusters: A pooled analysis
TLDR
Early improvement in symptom clusters significantly predicts symptomatic or functional remission at week 8 in patients with depression receiving desvenlafaxine or placebo, and patients without early improvement were less likely to remit.
Adjunctive Trazodone and Depression Outcome in Adolescents Treated with Serotonin Re-uptake Inhibitors.
  • M. A. Sultan, D. Courtney
  • Psychology, Medicine
    Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent
  • 2017
TLDR
Exposure to trazodone exposure was associated with treatment non-response in adolescents taking SRIs, and future randomized controlled trials of traZodone in samples of adolescents takingSRIs for depression are warranted.
Efficacy and tolerability of Z-drug adjunction to antidepressant treatment for major depressive disorder: a systematic review and meta-analysis of randomized controlled trials
TLDR
In conclusion, Z-drugs + antidepressants improves the treatment efficacy for MDD compared with the placebo-+-antidepressant-alone-controlled trials, however, the therapy requires close monitoring of adverse events, particularly dizziness.
Low doses of mirtazapine or quetiapine for transient insomnia: A randomised, double-blind, cross-over, placebo-controlled trial
TLDR
The use of low doses of mirtazapine and quetiapine for the treatment of insomnia support the use of these drugs on the long-term effects regarding effectiveness and adverse effects.
[Drug-induced insomnia in old and very old patients].
TLDR
The authors present the frequency of insomnia associated with taking drugs from different pharmacological groups according to the literature, and consider mechanisms of insomnia development due to the effect on various receptors and neurotransmitter systems.
...
1
2
3
4
...

References

SHOWING 1-10 OF 69 REFERENCES
Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine.
TLDR
Agomelatine showed similar antidepressant efficacy with earlier and greater efficacy in improving subjective sleep than venlafaxine in MDD patients.
Agomelatine: a preliminary review of a new antidepressant.
TLDR
Agomelatine appears to be as efficacious in treating MDD as other antidepressants but with fewer adverse effects, and appears to improve sleep quality and ease of falling asleep, as measured subjectively in depressed patients.
Antidepressants and their effect on sleep
TLDR
The effect on sleep varies between compounds within antidepressant classes, differences relating to the amount of sedative or alerting (insomnia) effects, changes to baseline sleep parameters, Differences relating to REM sleep, and the degree of sleep‐related side effects.
Insomnia improvement during antidepressant treatment and CLOCK gene polymorphism
  • A. Serretti, C. Cusin, E. Smeraldi
  • Psychology
    American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics
  • 2005
TLDR
The findings may suggest that CLOCK genotype influences the time course of insomnia during antidepressant treatment, and together with previous findings on this polymorphism could lead to a further dissection of the complexity of mood disorders.
Treatment-Emergent Sexual Dysfunction Related to Antidepressants: A Meta-Analysis
TLDR
Treatment-emergent SD caused by antidepressants is a considerable issue with a large variation across compounds and should be considered in clinical activity for the choice of the prescribed drug.
A preliminary study of fluvoxamine maleate on depressive state and serum melatonin levels in patients after cerebral infarction.
TLDR
The administration of fluvoxamine to patients with depressive state after cerebral infarction alleviated both the depressive state and sleep disturbances and increased melatonin levels may contribute to improvement in sleep disturbance, one of the major symptoms of depression.
Chronotherapeutics (light and wake therapy) in affective disorders.
TLDR
Given the urgent need for new strategies to treat patients with residual depressive symptoms, clinical trials of wake therapy and/or adjuvant light therapy, coupled with follow-up studies of long-term recurrence, are a high priority.
Fluvoxamine versus fluoxetine in major depressive episode: a double‐blind randomised comparison
TLDR
The findings of this study indicate that fluvoxamine may have a faster onset of action with respect to resolution of depressive symptoms and result in a better improvement in sleep quality.
Bupropion: a review of its use in the management of major depressive disorder.
TLDR
Available clinical data suggest that bupropion is an effective and generally well tolerated option in the treatment of MDD, with the newer formulations having the advantage of reduced frequency of daily administration.
...
1
2
3
4
5
...